• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Malaysian Deputy Prime Minister Attends Groundbreaking Ceremony of Gan & Lee Pharmaceuticals' Partner Factory
    Malaysian Deputy Prime Minister Attends Groundbreaking Ceremony of Gan & Lee Pharmaceuticals' Partner Factory
    Date:2024-11-11

    On October 30th, a significant groundbreaking ceremony was held for an insulin formulation filling plant, which is a client project of Gan & Lee Pharmaceuticals (stock code: 603087.SH). The ceremony was attended by Malaysia's Deputy Prime Minister, YAB Dato’ Sri Haji Fadillah Bin Haji Yusof, and the former Second Finance Minister, Nor Mohamed Yakcop. Also present were Du Kai, the CEO of Gan & Lee Pharmaceuticals, and members of the company's Asia-Pacific international business team. Their presence highlighted the importance of the event, which symbolizes the deep cooperation between China and Malaysia in the biomedical industry.

     

    During the ceremony, Mr. Du Kai engaged in friendly discussions with the Deputy Prime Minister and the former Finance Minister. The establishment of the factory will have a profound impact on alleviating the current medical resource shortage faced by Malaysia. Since August 2024, Malaysia has been experiencing a nationwide shortage of insulin. In this critical situation, Gan & Lee Pharmaceuticals, in collaboration with its Malaysian partner, promptly submitted a proposal to the Ministry of Health Malaysia. The proposal introduced a third-generation insulin analog that offers improved efficacy, safety, and convenience compared to the existing second-generation human insulin. The project is currently progressing actively and orderly Mr. Du highlighted Gan & Lee Pharmaceuticals’ dedication to patient care and its commitment to assisting the Malaysian government in overcoming the insulin shortage. “We are honored to contribute to the development of Malaysia’s local insulin production capabilities and to enhance the accessibility of medical treatments in the region,” he stated.

     

    Over the past decade, Gan & Lee Pharmaceuticals has actively participated in the Belt and Road Initiative, establishing international partnerships and business operations in more than 20 countries and regions, including Turkey and Kazakhstan. The company has particularly gained substantial experience in localizing insulin production in large markets such as Indonesia, Brazil, Argentina, and Turkey. Gan & Lee Pharmaceuticals plans to leverage its production technology strengths and extensive experience in overseas technology transfer to facilitate the implementation of third-generation insulin filling technology for Malaysian enterprises. By introducing cost-effective products, the company aims to accelerate the shift in the Malaysian insulin market from second- to third-generation products. This collaboration not only strengthens business ties in the biomedical sector between the two countries but also positively impacts the health and well-being of the Malaysian population. Moving forward, Gan & Lee Pharmaceuticals remains committed to the spirit of the Belt and Road Initiative, working to deepen its relationships with global partners and to provide high-quality medications and services to patients worldwide.


    About Gan & Lee

    Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

     

    In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 扁豆传媒视频免费观看| 精品乱子伦一区二区三区| 日韩精品久久一区二区三区| 国产精品免费观看视频播放| 亚洲欧美日韩另类在线专区| 99热在线精品播放| 正在播放露脸一区| 国产线视频精品免费观看视频| 亚洲精彩视频在线观看| 999zyz色资源站在线观看| 激情综合一区二区三区| 国产黄三级高清在线观看播放 | 扒下胸罩揉她的乳尖调教| 国产三级在线观看视频不卡| 久久久精品免费| 色一情一乱一伦一区二区三区| 日本中文在线视频| 哒哒哒免费视频观看在线www| 中文字幕avdvd| 精品久久久久久久免费人妻| 女人和拘做受口述| 亚洲第一精品福利| www.免费在线观看| 色多多免费视频观看区一区| 无人视频免费观看免费直播在线观看 | 亚洲精品www| 2021最新国产成人精品视频| 欧美a级毛欧美1级a大片免费播放| 国产成人永久免费视频| 久久99精品久久久久久水蜜桃| 综合图区亚洲欧美另类小说| 天天操天天干天天操| 亚洲欧洲日产国产最新| 免费a在线观看| 日日躁夜夜躁狠狠躁超碰97| 又粗又长又黄又爽视频| 99国产精品自在自在久久| 欧美专区在线视频| 国产免费av一区二区三区| 一级做a爰片性色毛片新版的| 激情五月激情综合|